Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Victor B Talisa
Florian B Mayr
Adeel A Butt

Showing results (1-10 of 327) with videos related to

Pageof 33
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Reply to Wirth et alVictor B Talisa, Florian B Mayr, Adeel A Butt
The New England Journal of Medicine|February 9, 2022
Effectiveness of Homologous or Heterologous Covid-19 Boosters in VeteransFlorian B Mayr, Victor B Talisa, Obaid Shaikh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2022
Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron VariantAdeel A Butt, Victor B Talisa, Obaid S Shaikh, et al.
Open Forum Infectious Diseases|July 26, 2022
Comparative COVID-19 Vaccine Effectiveness Over Time in VeteransFlorian B Mayr, Victor B Talisa, Obaid S Shaikh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 4, 2022
Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National PopulationAdeel A Butt, Victor B Talisa, Peng Yan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2022
Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic HemodialysisAdeel A Butt, Victor B Talisa, Peng Yan, et al.
The Journal of Infectious Diseases|September 15, 2023
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort StudyAdeel A Butt, Peng Yan, Obaid S Shaikh, et al.
The Journal of Infectious Diseases|June 1, 2023
Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19Adeel A Butt, Peng Yan, Obaid S Shaikh, et al.
Nature Communications|June 25, 2022
COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periodsFlorian B Mayr, Victor B Talisa, Alexander D Castro, et al.
JAMA Network Open|October 25, 2022
Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19Alexander D Castro, Florian B Mayr, Victor B Talisa, et al.
Pageof 33

Showing results (1-10 of 327) with videos related to

Sort By:
Pageof 33
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 30, 2022
Reply to Wirth et alVictor B Talisa, Florian B Mayr, Adeel A Butt
The New England Journal of Medicine|February 9, 2022
Effectiveness of Homologous or Heterologous Covid-19 Boosters in VeteransFlorian B Mayr, Victor B Talisa, Obaid Shaikh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 5, 2022
Relative Vaccine Effectiveness of a Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine Booster Dose Against the Omicron VariantAdeel A Butt, Victor B Talisa, Obaid S Shaikh, et al.
Open Forum Infectious Diseases|July 26, 2022
Comparative COVID-19 Vaccine Effectiveness Over Time in VeteransFlorian B Mayr, Victor B Talisa, Obaid S Shaikh, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 4, 2022
Vaccine Effectiveness of 3 Versus 2 Doses of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in a High-Risk National PopulationAdeel A Butt, Victor B Talisa, Peng Yan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 9, 2022
Real-World Effectiveness of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccines in Preventing Confirmed Infection in Patients on Chronic HemodialysisAdeel A Butt, Victor B Talisa, Peng Yan, et al.
The Journal of Infectious Diseases|September 15, 2023
Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort StudyAdeel A Butt, Peng Yan, Obaid S Shaikh, et al.
The Journal of Infectious Diseases|June 1, 2023
Molnupiravir Use and 30-Day Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-risk Population With COVID-19Adeel A Butt, Peng Yan, Obaid S Shaikh, et al.
Nature Communications|June 25, 2022
COVID-19 disease severity in US Veterans infected during Omicron and Delta variant predominant periodsFlorian B Mayr, Victor B Talisa, Alexander D Castro, et al.
JAMA Network Open|October 25, 2022
Variation in Clinical Treatment and Outcomes by Race Among US Veterans Hospitalized With COVID-19Alexander D Castro, Florian B Mayr, Victor B Talisa, et al.
Pageof 33